Article Sidebar

PDF (Tiếng Việt)
Published: 2025-02-27
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v187i2.3080
Issue
Vol. 187 No. 2 (2025)
Section
Các bài báo
How to Cite
Huyền, T. T., Phương, P. T. M., & Doanh, L. H. (2025). 19. Serological diagnosis of herpes simplex virus 1,2 in patients with erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Journal of Medical Research, 187(2), 166-175. https://doi.org/10.52852/tcncyh.v187i2.3080

19. Serological diagnosis of herpes simplex virus 1,2 in patients with erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Tran Thi Huyen, Pham Thi Minh Phuong, Le Huu Doanh

Main Article Content

Abstract

This cross-sectional descriptive study was conducted in 54 patients with erythema multiform (EM), 30 patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and 30 healthy controls to determine the seropositivity rates for herpes simplex virus types 1 and 2 (HSV1, 2) and their correlation with certain clinical features. The results showed that the seropositivity rates for HSV1, 2 - IgM in the SJS/TEN group, the EM group, and the healthy group were 20%, 22.22%, and 6.67%, respectively, with no significant difference between groups. The seropositivity rate for HSV1, 2 - IgG was relatively high across all three groups, with the SJS/TEN group showing a higher rate than the EM group (100% vs. 87.4%, p < 0.05). Among the EM group, the HSV1, 2 - IgM seropositivity rate was higher in patients under 30 years old compared to those aged 30 years or older; conversely, the HSV1, 2 - IgG seropositivity rate was higher in patients aged 30 years or older than in those under 30 years old. Furthermore, the HSV1, 2 - IgG seropositivity rate was higher in patients with diffuse lesions than in those with focal, acral lesions (p < 0.05). However, the HSV1, 2 - IgM seropositivity rate was higher in patients with focal, acral lesions (50%) than in those with diffuse lesions (18.75%), p > 0.05.

Article Details

Keywords

Erythema multiforme, herpes simplex virus, Stevens-Johnson syndrome, toxic epidermal necrolysis

References

1. Kechichian E, Dupin N, Wetter DA, Ortonne N, Agbo-Godeau S, Chosidow O. Erythema multiforme. EClinicalMedicine. 2024; 77: 102909. doi:10.1016/j.eclinm.2024.102909.
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1): 92-96.
3. Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015; 5(2): 68-77. doi:10.5415/apallergy.2015.5.2.68.
4. Tagajdid MR, Doblali T, Elannaz H, Hammi S, Belfequih B, Mrani S. Reactivation of cytomegalovirus in a patient with stevens-johnson syndrome-toxic epidermal necrolysis. Iran J Med Sci. 2013; 38(2 Suppl): 195-197.
5. Muhd Besari A, Lim JA, Vellaichamy PT, Hussain FA, Kamaludin Z, Nor M. Stevens-Johnson syndrome as a primary skin manifestation of COVID-19. Postgrad Med J. Published online October 20, 2021: postgradmedj-2021-140778. doi:10.1136/postgradmedj-2021-140778.
6. Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017; 137(5): 1065-1073. doi:10.1016/j.jid.2016.11.034.
7. Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diagn Ther. 2006; 10(1): 17-28. doi:10.1007/BF03256439.
8. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013; 57(4): 583-596. doi:10.1016/j.cden.2013.07.001.
9. Akkurt ZM, Uçmak D, Türkcü G, Yüksel H, Yildiz K, Arıca M. Expression of interleukin-17 in lesions of erythema multiforme may indicate a role for T helper 17 cells. Cent-Eur J Immunol. 2014;39(3):370-376. doi:10.5114/ceji.2014.45950
10. Ng PPL, Sun YJ, Tan HH, Tan SH. Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Dermatol Basel Switz. 2003; 207(4): 349-353. doi:10.1159/000074112.
11. Aslanzadeh J, Helm KF, Espy MJ, Muller SA, Smith TF. Detection of HSV-specific DNA in biopsy tissue of patients with erythema multiforme by polymerase chain reaction. Br J Dermatol. 1992; 126(1): 19-23. doi:10.1111/j.1365-2133.1992.tb08397.x.
12. Cheriyan S, Patterson R. Recurrent Stevens-Johnson syndrome secondary to herpes simplex: a follow up on a successful management program. Allergy Asthma Proc. 1996; 17(2): 71-73. doi:10.2500/108854196778645056.
13. Roselli J, Innocenti T, Lynch EN, et al. Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease. Case Rep Gastrointest Med. 2020; 2020: 3875024. doi:10.1155/2020/3875024.
14. Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy. 2004; 59(1): 118. doi:10.1046/j.1398-9995.2003.00336.x.
15. Miyachi M, Imafuku S. Incidence of serum antibody titers against herpes simplex virus in Japanese patients. J Dermatol. 2017; 44(1): 47-51. doi:10.1111/1346-8138.13506.